BioCentury | Jul 21, 2020
Product Development

Data Bytes: COVID-19 pipeline still growing

...oral HIF-PH inhibitor Vafseo from Akebia Therapeutics Inc. (NASDAQ:AKBA) and the NK1R antagonist Cinvanti from Heron Therapeutics Inc....
BioCentury | Feb 21, 2020
Product Development

Feb. 20 Product Development Quick Takes: Priority Review puts BioMarin on track to score first hemophilia gene therapy approval in U.S.; plus Gilead-CDC, Genfit

...The therapy is already approved as maintenance treatment of COPD. Heron PDUFA extended to June Heron Therapeutics Inc....
...furoate/vilanterol/umeclidinium, fluticasone furoate/umeclidinium/vilanterol, FF/UMEC/VI (GSK2834425) BioMarin Pharmaceutical Inc. Gilead Sciences Inc. Genfit S.A. Teva Pharmaceutical Industries Ltd. ForteBio Inc. Tocagen Inc. GlaxoSmithKline plc Heron Therapeutics Inc. Immatics...
BioCentury | Oct 29, 2019
Company News

Oct. 28 Company Quick Takes: MOR106 dropped in atopic dermatitis; plus Blueprint, Merus, Gilead-Glympse, Heron and GSK

...terms are undisclosed (see "A Glympse at Drug Response" ). FDA accepts Heron NDA resubmission Heron Therapeutics Inc....
...NRG1 (HRG1) - Neuregulin 1; PDGFRα (PDGFR2; CD140A) - platelet derived growth factor receptor α BioCentury Staff HTX-011 MOR106 Heron Therapeutics Inc. GlaxoSmithKline...
BioCentury | Oct 4, 2019
Financial News

Oct. 4 Financial Quick Takes: Innovent raises $300M in Hong Kong's first biotech follow-on; plus Oyster Point, Heron, Molecular Assemblies and Geneoscopy

...stock picker’s market in 4Q19 (see BioCentury’s 4Q19 Financial Markets Preview ). Heron raises $150M Heron Therapeutics Inc....
...quantifying eukaryotic RNA isolated from epithelial cells in stool. Elizabeth S. Eaton Innovent Biologics Inc. Oyster Point Pharma Inc. Heron Therapeutics Inc. Molecular...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

...BSE:532296) FDA issues a complete response letter for Ryaltris mometasone/olopatadine to treat seasonal allergic rhinitis Heron Therapeutics Inc....
BioCentury | May 1, 2019
Company News

May 1 Company Quick Takes: Heron, Nabriva, Allergan, GSK, Merck, Alnylam

...Complete response letter for Heron’s non-opioid pain therapy Heron Therapeutics Inc. (NASDAQ:HRTX) was off $3.93 (18%) to $17.75...
...fosfomycin (Zolyd, ZTI-01) HTX-011 Onpattro, patisiran (ALN-TTR02, GENZ438027, GZ438027, SAR438027) Shingrix (GSK1437173A, hz/su, Herpes zoster vaccine) Alnylam Pharmaceuticals Inc. GlaxoSmithKline plc Heron Therapeutics Inc. Merck...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...cannabidiol Reduce seizure frequency in patients with tuberous sclerosis complex (TSC) Phase III data 2Q19 Heron Therapeutics Inc....
BioCentury | Feb 6, 2019
Company News

Management tracks: Astellas, Blueprint

...precision therapy company said both will continue in their prior roles. Pain and cancer company Heron Therapeutics Inc....
BioCentury | Jan 5, 2019
Finance

Ready to launch

...plc (NASDAQ:GWPH) Epidiolex cannabidiol Seizures associated with Dravet syndrome or Lennox-Gastaut syndrome EC action 1Q19 Heron Therapeutics Inc....
BioCentury | Jan 4, 2019
Clinical News

Heron's non-opioid HTX-011 gets Priority Review

...FDA accepted and granted Priority Review to an NDA for HTX-011 from Heron Therapeutics Inc. (NASDAQ:HRTX) for postoperative...
...$2.19 to $25.94 on Dec. 31. Heron Therapeutics Inc. (NASDAQ:HRTX), San Diego, Calif. Product: HTX-011 Business: Neurology Jennie Walters HTX-011 Heron Therapeutics Inc....
Items per page:
1 - 10 of 77
BioCentury | Jul 21, 2020
Product Development

Data Bytes: COVID-19 pipeline still growing

...oral HIF-PH inhibitor Vafseo from Akebia Therapeutics Inc. (NASDAQ:AKBA) and the NK1R antagonist Cinvanti from Heron Therapeutics Inc....
BioCentury | Feb 21, 2020
Product Development

Feb. 20 Product Development Quick Takes: Priority Review puts BioMarin on track to score first hemophilia gene therapy approval in U.S.; plus Gilead-CDC, Genfit

...The therapy is already approved as maintenance treatment of COPD. Heron PDUFA extended to June Heron Therapeutics Inc....
...furoate/vilanterol/umeclidinium, fluticasone furoate/umeclidinium/vilanterol, FF/UMEC/VI (GSK2834425) BioMarin Pharmaceutical Inc. Gilead Sciences Inc. Genfit S.A. Teva Pharmaceutical Industries Ltd. ForteBio Inc. Tocagen Inc. GlaxoSmithKline plc Heron Therapeutics Inc. Immatics...
BioCentury | Oct 29, 2019
Company News

Oct. 28 Company Quick Takes: MOR106 dropped in atopic dermatitis; plus Blueprint, Merus, Gilead-Glympse, Heron and GSK

...terms are undisclosed (see "A Glympse at Drug Response" ). FDA accepts Heron NDA resubmission Heron Therapeutics Inc....
...NRG1 (HRG1) - Neuregulin 1; PDGFRα (PDGFR2; CD140A) - platelet derived growth factor receptor α BioCentury Staff HTX-011 MOR106 Heron Therapeutics Inc. GlaxoSmithKline...
BioCentury | Oct 4, 2019
Financial News

Oct. 4 Financial Quick Takes: Innovent raises $300M in Hong Kong's first biotech follow-on; plus Oyster Point, Heron, Molecular Assemblies and Geneoscopy

...stock picker’s market in 4Q19 (see BioCentury’s 4Q19 Financial Markets Preview ). Heron raises $150M Heron Therapeutics Inc....
...quantifying eukaryotic RNA isolated from epithelial cells in stool. Elizabeth S. Eaton Innovent Biologics Inc. Oyster Point Pharma Inc. Heron Therapeutics Inc. Molecular...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

...BSE:532296) FDA issues a complete response letter for Ryaltris mometasone/olopatadine to treat seasonal allergic rhinitis Heron Therapeutics Inc....
BioCentury | May 1, 2019
Company News

May 1 Company Quick Takes: Heron, Nabriva, Allergan, GSK, Merck, Alnylam

...Complete response letter for Heron’s non-opioid pain therapy Heron Therapeutics Inc. (NASDAQ:HRTX) was off $3.93 (18%) to $17.75...
...fosfomycin (Zolyd, ZTI-01) HTX-011 Onpattro, patisiran (ALN-TTR02, GENZ438027, GZ438027, SAR438027) Shingrix (GSK1437173A, hz/su, Herpes zoster vaccine) Alnylam Pharmaceuticals Inc. GlaxoSmithKline plc Heron Therapeutics Inc. Merck...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...cannabidiol Reduce seizure frequency in patients with tuberous sclerosis complex (TSC) Phase III data 2Q19 Heron Therapeutics Inc....
BioCentury | Feb 6, 2019
Company News

Management tracks: Astellas, Blueprint

...precision therapy company said both will continue in their prior roles. Pain and cancer company Heron Therapeutics Inc....
BioCentury | Jan 5, 2019
Finance

Ready to launch

...plc (NASDAQ:GWPH) Epidiolex cannabidiol Seizures associated with Dravet syndrome or Lennox-Gastaut syndrome EC action 1Q19 Heron Therapeutics Inc....
BioCentury | Jan 4, 2019
Clinical News

Heron's non-opioid HTX-011 gets Priority Review

...FDA accepted and granted Priority Review to an NDA for HTX-011 from Heron Therapeutics Inc. (NASDAQ:HRTX) for postoperative...
...$2.19 to $25.94 on Dec. 31. Heron Therapeutics Inc. (NASDAQ:HRTX), San Diego, Calif. Product: HTX-011 Business: Neurology Jennie Walters HTX-011 Heron Therapeutics Inc....
Items per page:
1 - 10 of 77